Pharmacyclics has entered into a pharma alliance agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of IMBRUVICA (ibrutinib)in combination with GAZYVA (obinutuzumab).Imbruvica is an oral Bruton's tyrosine kinase (BTK) inhibitor.
Gazyva is a new CD20-directed antibody that attacks targeted cells both directly and together with the body's immune system, in patients with non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
The agreement allows for multiple studies to be considered and conducted.
Initially, a Phase 3 study will be conducted by Pharmacyclics in CLL/SLL.
Plans to evaluate the combination for NHL currently are in development.
Both products are approved and marketed for the treatment of CLL.
The use of these products in combination is investigational only.
For further deal information visit Current Agreements (subscription required)
Report: Partnering Deals and Alliances with Roche
Report: Top 50 Big Biotech Partnering and M&A Deal Trends
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity